ProQR Therapeutics (PRQR) Non-Current Deffered Revenue (2021 - 2025)

ProQR Therapeutics' Non-Current Deffered Revenue history spans 4 years, with the latest figure at $31.4 million for Q4 2024.

  • For Q4 2024, Non-Current Deffered Revenue fell 33.83% year-over-year to $31.4 million; the TTM value through Dec 2024 reached $31.4 million, down 33.83%, while the annual FY2024 figure was $31.9 million, 33.34% down from the prior year.
  • Non-Current Deffered Revenue for Q4 2024 was $31.4 million at ProQR Therapeutics, down from $47.5 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $66.9 million in Q4 2022 and bottomed at $16.8 million in Q4 2021.
  • The 4-year median for Non-Current Deffered Revenue is $39.5 million (2024), against an average of $40.7 million.
  • The largest annual shift saw Non-Current Deffered Revenue surged 298.15% in 2022 before it tumbled 33.83% in 2024.
  • A 4-year view of Non-Current Deffered Revenue shows it stood at $16.8 million in 2021, then soared by 298.15% to $66.9 million in 2022, then fell by 28.96% to $47.5 million in 2023, then crashed by 33.83% to $31.4 million in 2024.
  • Per Business Quant, the three most recent readings for PRQR's Non-Current Deffered Revenue are $31.4 million (Q4 2024), $47.5 million (Q4 2023), and $66.9 million (Q4 2022).